Pharma BD Deal Intelligence
BioNTech announced agreement to acquire Biotheus for $800M upfront (cash + small portion ADS) plus up to $150M in contingent milestones, total up to $950M. Deal deepens BNT327 program, a PD-L1/VEGF-A bispecific antibody being tested in 700+ patients across multiple tumor types as a pan-tumor platform for combinations. BNT327/PM8002 has since received the INN/generic name pumitamig (BMS code BMS-986545); in June 2025 BioNTech partnered it with Bristol Myers Squibb in a global 50/50 co-development/co-commercialization deal ($1.5B upfront, up to ~$11.1B total). As of mid-2026 pumitamig is in a pivotal global Phase 3 program — ROSETTA Lung-01 (first-line extensive-stage SCLC vs atezolizumab+chemo) and ROSETTA Lung-02 (first-line NSCLC vs pembrolizumab+chemo, 1500 mg Q3W dose selected) — with 2026 Phase 2 NSCLC data showing confirmed ORR up to 63.6% (non-squamous) and 72.7% (squamous).